Finding a lower biomarker level in a patient group does not establish that replacing the measured substance will improve the condition. This is the central boundary for an older DSIP report. Primary study
What was observed
The investigators measured cerebrospinal-fluid DSIP in healthy volunteers and hospitalized people with schizophrenia or major depressive disorders. Both patient groups had lower measured levels. The report also described exploratory sex and sleep-disturbance patterns and no significant change associated with neuroleptic treatment. This was not a DSIP administration trial. Primary report
Our appraisal: association does not define deficiency
A difference between group averages can arise from disease processes, treatment, sampling conditions, or other characteristics. Establishing a deficiency requires more than identifying the lower group. It needs an interpretable reference framework and evidence linking the measurement to a clinically meaningful state.
The temporal direction is unresolved by a group comparison. Lower levels might precede symptoms, follow them, or be associated through another factor. An intervention aimed at changing the marker therefore cannot be assumed to change the disease.
Assay specificity is especially important when interpreting historical peptide measurements. The reader should examine what molecular forms the assay recognized, its detection limits, specimen handling, and whether measured immunoreactivity was established to represent the exact intact peptide of interest.
Exploratory correlations and sex differences should retain their uncertainty rather than becoming diagnostic cutoffs or responder-selection rules. A nonsignificant medication comparison likewise does not prove medication has no influence under every circumstance.
This report is best treated as an observational biomarker hypothesis. It does not establish a diagnostic test, demonstrate a cause of psychiatric illness, or provide a rationale for unsupervised DSIP replacement. Further work would need validated measurement, longitudinal replication, and separately justified intervention studies.
Frequently asked questions
Was DSIP administered as an intervention?
No.
Were lower measured levels reported in patient groups?
Yes.
Does a lower average establish a clinical deficiency?
No.
Does the comparison determine cause and effect?
No.
Can an exploratory correlation define a diagnostic cutoff?
No.
Why review assay specificity?
To establish which molecular signal was actually measured.
Does this justify replacement treatment?
Not by itself.